Financings in Brief: Metra Biosystems
This article was originally published in The Gray Sheet
Executive Summary
Metra Biosystems: Amends shareholder rights plan, raising from 15% to 20% the equity stake that a person or group must acquire to initiate the rights under the plan. "Upon the advice of our legal and financial advisors, and upon the analysis of the company's institutional shareholder base, the board of directors of Metra concluded that this change was in the best interests of Metra and its shareholders," the firm says...
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.